Product Description
Retinol stimulates fibroblasts to synthesize collagen fibres (stimulates the activity of fibroblasts and increases their number), improves skin elasticity (removes degenerated elastin fibers) and promotes angiogenesis (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791161/)
Mechanisms of Action: LXR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: CSIRO
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Poland
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bronchopulmonary Dysplasia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-516994-59-00 |
ASP-RET-CT001 | P2 |
Not yet recruiting |
Bronchopulmonary Dysplasia |
2026-03-31 |
2025-05-02 |
Treatments |